CN102712924A - 化疗药剂和TGF-β系统抑制剂的组合 - Google Patents

化疗药剂和TGF-β系统抑制剂的组合 Download PDF

Info

Publication number
CN102712924A
CN102712924A CN2010800436805A CN201080043680A CN102712924A CN 102712924 A CN102712924 A CN 102712924A CN 2010800436805 A CN2010800436805 A CN 2010800436805A CN 201080043680 A CN201080043680 A CN 201080043680A CN 102712924 A CN102712924 A CN 102712924A
Authority
CN
China
Prior art keywords
tgf
cancer
carcinoma
pharmaceutical composition
antisense oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800436805A
Other languages
English (en)
Chinese (zh)
Inventor
卡尔-赫尔曼·施林根西彭
弗兰克·亚申斯基
塔尼亚·罗特哈马尔
安内利泽·施奈德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isarna Therapeutics GmbH
Original Assignee
Antisense Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41278403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102712924(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antisense Pharma GmbH filed Critical Antisense Pharma GmbH
Publication of CN102712924A publication Critical patent/CN102712924A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN2010800436805A 2009-07-30 2010-07-30 化疗药剂和TGF-β系统抑制剂的组合 Pending CN102712924A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09166893 2009-07-30
EP09166893.9 2009-07-30
PCT/EP2010/061152 WO2011012713A1 (en) 2009-07-30 2010-07-30 Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system

Publications (1)

Publication Number Publication Date
CN102712924A true CN102712924A (zh) 2012-10-03

Family

ID=41278403

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800436805A Pending CN102712924A (zh) 2009-07-30 2010-07-30 化疗药剂和TGF-β系统抑制剂的组合

Country Status (17)

Country Link
US (1) US8476246B2 (enExample)
EP (1) EP2340308B1 (enExample)
JP (1) JP2013500313A (enExample)
KR (1) KR20120107456A (enExample)
CN (1) CN102712924A (enExample)
AU (1) AU2010277554B2 (enExample)
BR (1) BR112012002102A2 (enExample)
CA (1) CA2769618A1 (enExample)
CL (1) CL2012000247A1 (enExample)
CO (1) CO6511199A2 (enExample)
EC (1) ECSP12011689A (enExample)
IL (1) IL217821A0 (enExample)
IN (1) IN2012DN00969A (enExample)
MX (1) MX2012001244A (enExample)
PE (1) PE20121495A1 (enExample)
RU (1) RU2012107535A (enExample)
WO (1) WO2011012713A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI600430B (zh) * 2016-02-09 2017-10-01 奧圖泰利克有限責任公司 用於治療胰臟癌之組合物及方法
CN112933238A (zh) * 2021-02-02 2021-06-11 石河子大学 抑制TGF-βR1基因表达的物质与顺铂在治疗和/或预防食管癌中的应用
CN113425855A (zh) * 2021-06-28 2021-09-24 深圳市瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
CN113966342A (zh) * 2019-06-05 2022-01-21 Io生物技术公司 TGF-β疫苗

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101265180B1 (ko) * 2002-01-17 2013-05-29 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
TWI454281B (zh) * 2011-10-06 2014-10-01 Nat Univ Tsing Hua 硼酸於硼中子捕獲治療肝癌之用途
WO2013124869A2 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations
US20140275214A1 (en) * 2013-03-14 2014-09-18 Teva Pharmaceutical Industries, Ltd. Custirsen treatment with reduced toxicity
CA2949574C (en) * 2014-05-23 2022-06-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for determining whether a patient will achieve a response after radiation therapy
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
US11759530B2 (en) * 2014-11-17 2023-09-19 City Of Hope TKI permeability enhancers
CN108139375A (zh) 2015-06-26 2018-06-08 贝斯以色列女执事医疗中心股份有限公司 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer
KR20180103817A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
JP2021512956A (ja) 2018-02-06 2021-05-20 ザ ジェネラル ホスピタル コーポレイション 腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ
EP3937980A4 (en) * 2019-03-14 2023-08-02 The Research Foundation for The State University of New York Modified micrornas and their use in the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059133A2 (en) * 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
CN1845733A (zh) * 2003-09-04 2006-10-11 学校法人日本大学 TGF－β基因表达抑制剂
CN1902488A (zh) * 2003-11-13 2007-01-24 健泰科生物技术公司 肿瘤治疗的筛选实验和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
EP0856579A1 (en) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
KR20060127409A (ko) * 2003-11-13 2006-12-12 제넨테크, 인크. 종양 치료 방법 및 스크리닝 검정
CA2558667A1 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Antisense oligonucleotides for inhibiting the formation of metastases in cancer
US20090186076A1 (en) * 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent
JP5322476B2 (ja) * 2008-03-31 2013-10-23 テルモ株式会社 リポソームの製造装置およびリポソームの製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1845733A (zh) * 2003-09-04 2006-10-11 学校法人日本大学 TGF－β基因表达抑制剂
CN1902488A (zh) * 2003-11-13 2007-01-24 健泰科生物技术公司 肿瘤治疗的筛选实验和方法
WO2005059133A2 (en) * 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI600430B (zh) * 2016-02-09 2017-10-01 奧圖泰利克有限責任公司 用於治療胰臟癌之組合物及方法
CN113966342A (zh) * 2019-06-05 2022-01-21 Io生物技术公司 TGF-β疫苗
CN112933238A (zh) * 2021-02-02 2021-06-11 石河子大学 抑制TGF-βR1基因表达的物质与顺铂在治疗和/或预防食管癌中的应用
CN113425855A (zh) * 2021-06-28 2021-09-24 深圳市瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
CN113425855B (zh) * 2021-06-28 2023-11-07 深圳瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用

Also Published As

Publication number Publication date
EP2340308A1 (en) 2011-07-06
WO2011012713A1 (en) 2011-02-03
US20120027873A1 (en) 2012-02-02
RU2012107535A (ru) 2013-09-10
JP2013500313A (ja) 2013-01-07
CL2012000247A1 (es) 2013-07-05
IL217821A0 (en) 2012-03-29
US8476246B2 (en) 2013-07-02
CA2769618A1 (en) 2011-02-03
BR112012002102A2 (pt) 2017-05-02
AU2010277554B2 (en) 2015-02-19
CO6511199A2 (es) 2012-08-31
IN2012DN00969A (enExample) 2015-04-10
EP2340308B1 (en) 2014-12-24
MX2012001244A (es) 2012-03-26
AU2010277554A1 (en) 2012-03-01
PE20121495A1 (es) 2012-11-19
KR20120107456A (ko) 2012-10-02
ECSP12011689A (es) 2012-06-29

Similar Documents

Publication Publication Date Title
CN102712924A (zh) 化疗药剂和TGF-β系统抑制剂的组合
AU2004299670B2 (en) Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US20030055014A1 (en) Inhibition of angiogenesis by nucleic acids
ES2718082T3 (es) Tratamiento contra el cáncer
EP2004177B1 (en) Nitrofuran compounds for the treatment of cancer and angiogenesis
US12303494B2 (en) Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
KR20080075107A (ko) 면역조절성 올리고데옥시뉴클레오티드를 사용하는 조합물및 방법
KR101843985B1 (ko) 암을 치료하기 위한 조성물과 방법
CN117343965B (zh) 核酸载体、核酸药及其制备方法和应用
WO2005099773A1 (en) Use of erythropoietin for treatment of cancer
JP2022506958A (ja) Ｍｉｒ－１０ｂ活性を調節するためのマイクロｒｎａ化合物及び方法
WO2021245219A1 (en) A dbait molecule in combination with kras inhibitor for the treatment of cancer
EP2248895A2 (en) Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US20220168422A1 (en) Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
US20200181711A1 (en) Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
US20220233539A1 (en) Compositions and methods for inhibiting hedgehog pathway
US20220233543A1 (en) Compositions and methods for monitoring, diagnosis, detection and treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20121003

RJ01 Rejection of invention patent application after publication